Leap Therapeutics' anti-DKK1 antibody in combination with BeiGene's anti-PD-1 antibody demonstrated clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients. More news from Eluminex Bio, CTTQ, Neurophth, BeiGene and the CDE.
Innovent Biologics is licensing the Greater China rights to up to three enzyme-specific inhibitors from Amagma Therapeutics to strengthen its inflammatory disease portfolio. More news from Pharbers, BioTroy, Biocytogen, Neukio and Hengrui Pharma.
Mabwell is the 13th pre-revenue biotech startup listed on STAR. It raised RMB3.477 billion ($547 million) with an offer price of RMB34.8 apiece. It opened at RMB32 then further dropped to RMB24.5 to end the day.
Abbisko Therapeutics has inked a pact with Eli Lilly to develop and commercialise novel molecules against an undisclosed target for cardiometabolic diseases. More news from ReviR Therapeutics, Leman and SparX Bio.
CStone's study provides the only anti-PD-L1 immunotherapy plus chemotherapy option for squamous NSCLC patients worldwide. More news from Junsai, Gracell, BeyondSpring, HISUN, EastChina, Shenogen and Betta.
After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio.
Vibrant Therapeutics, a Guangzhou-based startup founded in 2019, closed a Series pre-A round to raise RMB100 million ($15.7 million) to accelerate AI-driven large molecule drug development. More news from Smart Nuclide, Hober Biotech, CStone and the CDE.
Coherus and Junshi Biosciences are planning late-stage clinical development of TIGIT-targeted antibody JS006 in combination with toripalimab in North America, and more news from Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics, Fosun Pharma and Insilico Medicine, Kexing Biopharm, Yizun Biomedical, Echo Biotec, Kyowa Kirin, Hisun Pharmaceutical, Betta Pharma, Hengrui Pharma and the ...
Incubated by Legend Capital, Binhu Biotech said it has raised nearly RMB200 million to develop universal cell and gene therapies for oncology, autoimmune diseases, and genetic diseases, and more news from Xellsmart, Youcare, BeiGene, CANbridge, Eli Lilly, JW Therapeutics and Chinese regulators.